Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA)
clinical trials that represent both patients' and physicians' priorities. Methods We …

Objective. To include the patient perspective in accordance with the Outcome Measures in
Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set …

Objectives—The current psoriatic arthritis (PsA) Core Domain Set defines core domains to
be measured in randomized controlled trials (RCTs) and longitudinal observational studies (…

Background/Purpose: Tobacco smoking and rheumatoid arthritis (RA) are independent risk
factors for short-term complications following total hip and total knee arthroplasty (THA/TKA). …

Introduction Persistent pain is a major concern for patients with psoriatic arthritis (PsA). Pain
may be due to inflammatory activity or augmented central pain processing. Unawareness of …

Psoriatic arthritis (PsA) is a chronic inflammatory disorder characterized by peripheral joint
inflammation, nail involvement, enthesitis, tenosynovitis and dactylitis, as well as increased …

… ., Pil Hoejgaard: None declared, Jeffrey Chau: None declared, Laura C Coates: None
declared, Vibeke Strand: None declared, Dafna D Gladman Grant/research support from: AbbVie, …

… ., Pil Hoejgaard: None declared, Laura C Coates: None declared, Vibeke Strand Consultant
of: AbbVie, Amgen, Biogen, Celltrion, Consortium of Rheumatology Researchers of North …

… We acknowledge all members of the GRAPPA-OMERACT PsA working group, which
includes the authors along with Laure Gossec, Pil Hoejgaard, Neil McHugh, Robin Christensen, …